
News|Articles|July 9, 2007
Latebreakers: Once daily PAH drug OK'd
Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
2
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5




























